Breast Disease pp 337-348 | Cite as

Male Breast Cancer

  • Abdullah IgciEmail author
  • Mustafa Tukenmez
  • Enver Özkurt


Breast cancer is observed in men 100-fold less often than in women. The risk of breast cancer in men is approximately 1 in 1000 throughout life. The American Association of Cancer predicted that 2360 men would be diagnosed with breast cancer in 2014 and that 430 male patients with breast cancer would die. The mean age of diagnosis of male breast cancer (MBC) is 67.7, which is 5–10 years older than for female breast cancer (FBC) patients in the USA, but in other parts of the world, such as the Middle East and South Asia, the age gap is smaller. Previous studies have shown that MBC cases are significantly different from female cases, whereas new studies have reported that breast cancer has similar characteristics at the same stages in both genders.


Male breast cancer Sentinel lymph node Mastectomy Axillary dissection Adjuvant therapy 


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012;62(4):220–41.PubMedCrossRefGoogle Scholar
  3. 3.
    American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society; 2014.Google Scholar
  4. 4.
    American Cancer Society. Cancer facts and figures 2018. Atlanta: American Cancer Society; 2018. Available online. Last accessed 27 Apr 2018.Google Scholar
  5. 5.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Nirmul D, Pegoraro RJ, Jialal I, Naidoo C, Joubert SM. The sex hormone profile of male patient with breast cancer. Br J Cancer. 1983;48(3):423–7.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Sanchez AG, Villanueva AG, Redondo C. Lobular carcinoma of the breast in a patient with Klinefelter’s syndrome. A case with bilateral, synchronous, histologically different breast tumors. Cancer. 1986;57(6):1181–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Schuchardt U, Seegenschmiedt MH, Kirschner MJ, Renner H, Sauer R. Adjuvant radiotherapy for breast carcinoma in men: a 20-year clinical experience. Am J Clin Oncol. 1996;19(4):330–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Gradishar WJ. Male breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborn CK, editors. Disease of the breast. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 661–7.Google Scholar
  11. 11.
    Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Crichlow RW, Galt SW. Male breast cancer. Surg Clin N Am. 1990;70(5):1165–77.PubMedCrossRefGoogle Scholar
  13. 13.
    Salehi A, Zeraati H, Mohammad K, Mahmoudi M, Talei AR, Ghaderi A, et al. Survival of male breast cancer in Fars, South of Iran. Iran Red Crescent Med J. 2011;13(2):99–105.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Tawil AN, Boulos FI, Chakhachiro ZI, Otrock ZK, Kandaharian L, El Saghir NS, et al. Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J. 2012;18(1):65–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Breast J Cancer. 1992;65:252–4.Google Scholar
  16. 16.
    Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, Dickinson BD. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep. 2010;24(5):1115–20. ReviewPubMedCrossRefGoogle Scholar
  17. 17.
    Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Larønningen S, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011;29(33):4381–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, López Gómez M, Casado E. Male breast cancer. Cancer Treat Rev. 2010;36(6):451–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Volpe CM, Raffetto JD, Collure DW, Hoover EL, Doerr RJ. Unilateral male breast masses: cancer risk and their evaluation and management. Am Surg. 1999;65(3):250–3.PubMedGoogle Scholar
  20. 20.
    Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA-2 mutation. Lancet. 1998;352(9137):1337–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Satram-Hoang S, Moran EM, Anton-Culver H, Burras RW, Heimann TM, Boggio I, et al. A pilot study of male breast cancer in the Veterans Affairs healthcare system. J Environ Pathol Toxicol Oncol. 2010;29(3):235–44.PubMedCrossRefGoogle Scholar
  22. 22.
    Winer EP, Morrow M, Osborne CK, Harris JR. Malignant tumors of the breast. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 1651–717.Google Scholar
  23. 23.
    Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114–22.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Marger D, Urdaneta N, Fischer JJ. Breast cancer in brothers: case reports and review of 30 cases of male breast cancer. Cancer. 1975;36(2):458–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Basham VM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res BCR. 2002;4(1):R2.PubMedCrossRefGoogle Scholar
  26. 26.
    Gilbert SF, Soliman AS, Karkouri M, Quinlan-Davidson M, Strahley A, Eissa M, et al. Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. Breast Dis. 2011;33(1):17–26.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Bishop DT. BRCA1 and BRCA2 and breast cancer incidence: a review. Ann Oncol. 1999;10(Suppl 6):113–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. J Med Genet. 2010;47(10):710–1.PubMedCrossRefGoogle Scholar
  29. 29.
    Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, et al. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat. 2012;134(1):411–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. 2011;126(3):771–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Blanco A, de la Hoya M, Balmana J, y Cajal TR, Teulé A, Miramar MD, et al. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat. 2012;132(1):307–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Gilbert SF, Soliman AS, Iniesta M, Eissa M, Hablas A, Seifeldin IA, et al. Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients. Breast Cancer Res Treat. 2011;129(2):575–81.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Silvestri V, Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat. 2010;122(1):299–301.PubMedCrossRefGoogle Scholar
  34. 34.
    Sauty de Chalon A, Teo Z, Park DJ, Odefrey FA, kConFab HJL, Southey MC. Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat. 2010;121(1):253–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, et al. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy. Breast Cancer Res Treat. 2011;126(2):539–43.PubMedCrossRefGoogle Scholar
  36. 36.
    Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Palli D, et al. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res. 2011;13(1):404.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Kizildag S, Gulsu E, Bagci O, Yuksel E, Canda T. Vitamin D receptor gene polymorphisms and male breast cancer risk in Turkish population. J BUON. 2011;16(4):640–5.PubMedGoogle Scholar
  38. 38.
    Fentiman IS, Fourguet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367:595–604.PubMedCrossRefGoogle Scholar
  39. 39.
    Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Ottini L, Masala G, D’Amico C, Mancini B, Saieva C, Aceto G, et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63:342–7.PubMedGoogle Scholar
  41. 41.
    Donegan WL, Redlich PN. Breast cancer in men. Surg Clin N Am. 1996;76(2):343–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Brinton LA. Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatr. 2011;100(6):814–8.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Male breast cancer. Crit Rev Oncol Hematol. 2010;73:141–55.PubMedCrossRefGoogle Scholar
  44. 44.
    Evans DB, Crichlow RW. Carcinoma of the male breast and Klinefelter’s syndrome: is there an association? CA Cancer J Clin. 1987;37(4):246–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Heller K, Rosen P, Schottenfeld D. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg. 1978;188:60–5.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med. 1996;335(11):823.PubMedCrossRefGoogle Scholar
  47. 47.
    Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014;106(3):djt465.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Rohrmann S, Shiels MS, Lopez DS, Rifai N, Nelson WG, Kanarek N, et al. Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes Control. 2011;22(8):1141–51.PubMedCrossRefGoogle Scholar
  49. 49.
    Moore MP, Harris RH, Lippman ME, Morrow M, Hellman S. Male breast cancer. diseases of the breast. 1st ed. Philadelphia: Lippincott-Raven; 1996. p. 859–63.Google Scholar
  50. 50.
    Sasco AJ, Lowenfels AB, Pasker-de Jong P. Epidemiology of male breast cancer: a meta analysis published case-control studies and discussion of selected a etiological factors. Int J Cancer. 1993;53(4):538–49.PubMedCrossRefGoogle Scholar
  51. 51.
    Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat. 2010;119(1):185–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Eldar S, Nash E, Abrahanson J. Radiation carcinogenesis in the male breast. Eur J Surg Oncol. 1989;15(3):274–8.PubMedGoogle Scholar
  53. 53.
    Villeneuve S, Cyr D, Lynge E, Orsi L, Sabroe S, Merletti F, et al. Occupation and occupational exposure to endocrine disrupting chemicals in male breast cancer: a case-control study in Europe. Occup Environ Med. 2010;67(12):837–44.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Hansen J. Elevated risk for male breast cancer after occupational exposure to gasoline and vehicular combustion products. Am J Ind Med. 2000;37(4):349–52.PubMedCrossRefGoogle Scholar
  55. 55.
    Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer a case-control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.PubMedCrossRefGoogle Scholar
  56. 56.
    Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, et al. Current management of male breast cancer: a review of 104 cases. Ann Surg. 1992;215(5):451–7.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males. A multi institutional survey. Cancer. 1998;83(3):498–509.PubMedCrossRefGoogle Scholar
  58. 58.
    Bezwoda WR, Hesdorffer C, Dansey R, de Moor N, Derman DP, Browde S, et al. Breast cancer in men: clinical features, hormone receptor status, and response to therapy. Cancer. 1987;60(6):1337–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 2013;24(6):1434–43.PubMedCrossRefGoogle Scholar
  60. 60.
    Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, et al. Chinese female breast cancer patients show a better overall survival than their male counterparts. Chin Med J. 2010;123(17):2347–52.PubMedGoogle Scholar
  61. 61.
    Gnerlich JL, Deshpande AD, Jeffe DB, Seelam S, Kimbuende E, Margenthaler JA. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to instage migration. Ann Surg Oncol. 2011;18(7):1837–44.PubMedCrossRefGoogle Scholar
  62. 62.
    Bourhafour M, Belbaraka R, Souadka A, M’rabti H, Tijami F, Errihani H. Male breast cancer: a report of 127 cases at a Moroccan institution. BMC Res Notes. 2011;4:219.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Wauters CAP, Kooistra BW, de Kievit-van der Heijden IM, Strobbe LJ. Is cytology useful in the diagnostic workup of male breast lesions? A retrospective study over a 16-year period and review of the recent literature. Acta Cytol. 2010;54:259–64.PubMedCrossRefGoogle Scholar
  64. 64.
    Doyle S, Steel J, Porter G. Imaging male breast cancer. Clin Radiol. 2011;66:1079–85.PubMedCrossRefGoogle Scholar
  65. 65.
    Jackson VP, Gilmor RL. Male breast carcinoma and gynecomastia: comparison of mammography with sonography. Radiology. 1983;149(2):533–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Kapdi CC, Parekh NJ. The male breast. Radiol Clin N Am. 1983;21(1):137–48.PubMedGoogle Scholar
  67. 67.
    Evans GF, Anthony T, Turnage RH. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg. 2001;181(2):96–100.PubMedCrossRefGoogle Scholar
  68. 68.
    Bhagat P, Kline TS. The male breast and malignant neoplasms. Diagnosis by aspiration biopsy cytology. Cancer. 1990;65(10):2338–41.PubMedCrossRefGoogle Scholar
  69. 69.
    Gill MS, Kayani N, Khan MN, Hasan SH. Breast diseases in males a morphological review of 150 cases. J Pak Med Assoc. 2000;50(6):177–9.PubMedGoogle Scholar
  70. 70.
    Tahmasebi S, Akrami M, Omidvari S, Salehi A, Talei A. Male breast cancer; analysis of 58 cases in Shiraz, South of Iran. Breast Dis. 2010;31(1):29–32.PubMedCrossRefGoogle Scholar
  71. 71.
    Arslan UY, Oksuzoglu B, Ozdemir N, Aksoy S, Alkış N, Gök A, et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29(2):554–60.PubMedCrossRefGoogle Scholar
  72. 72.
    Liukkonen S, Saarto T, Maenpaa H, Sjöström-Mattson J. Male breast cancer: a survey at the Helsinki University Central Hospital during 1981–2006. Acta Oncol. 2010;49(3):322–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol. 2013;24(Suppl 8):viii75–82.PubMedCrossRefGoogle Scholar
  74. 74.
    Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH. Molecular markers in male breast carcinoma. Cancer. 1998;83(9):1947–55.PubMedCrossRefGoogle Scholar
  75. 75.
    Kanthan R, Fried I, Rueckl T, Senger JL, Kanthan SC. Expression of cell cycle proteins in male breast carcinoma. World J Surg Oncol. 2010;8:10.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–17.PubMedGoogle Scholar
  77. 77.
    Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat. 2012;133(3):949–58.PubMedCrossRefGoogle Scholar
  78. 78.
    Zhou FF, Xia LP, Guo GF, Wang X, Yuan ZY, Zhang B, et al. Changes in therapeutic strategies in Chinese male patients with breast cancer: 40 years of experience in a single institute. Breast. 2010;19(6):450–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, et al. Male breast cancer: management and follow-up recommendations. Breast J. 2011;17(5):503–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Cloyd JM, Hernandez-Boussard T, Wapnir IL. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983–2009. Ann Surg Oncol. 2013;20(5):1545–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Elmi M, Sequeira S, Azin A, Elnahas A, McCready DR, Cil TD. Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database. Breast Cancer Res Treat. 2018; Scholar
  82. 82.
    Fogh S, Kachnic LA, Goldberg SI, Taghian AG, Powell SN, Hirsch AE. Localized therapy for male breast cancer: functional advantages with comparable outcomes using breast conservation. Clin Breast Cancer. 2013;13(5):344–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(5):561–4.CrossRefGoogle Scholar
  84. 84.
    Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med. 1992;117(9):771–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987;10(1):55–60.PubMedCrossRefGoogle Scholar
  86. 86.
    Patel HZ 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989;64(8):1583–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Fogh S, Hirsch AE, Langmead JP, Goldberg SI, Rosenberg CL, Taghian AG, et al. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. Clin Breast Cancer. 2011;11(1):39–45.PubMedCrossRefGoogle Scholar
  88. 88.
    Zhou FF, Xia LP, Wang X, Guo GF, Rong YM, Qiu HJ, et al. Analysis of prognostic factors in male breast cancer: a report of 72 cases from a single institution. Chin J Cancer. 2010;29(2):184–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010;17(5):17–21.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol. 2012;23(6):1471–4.PubMedCrossRefGoogle Scholar
  91. 91.
    Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994;74(1):74–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137(2):465–70.PubMedCrossRefGoogle Scholar
  93. 93.
    Abrams MJ, Koffer PP, Wazer DE, Hepel JT. Postmastectomy radiation therapy is associated with improved survival in node-positive male breast cancer: a population analysis. Int J Radiat Oncol Biol Phys. 2017;98(2):384–91.PubMedCrossRefGoogle Scholar
  94. 94.
    Yu E, Suzuki H, Younus J, Elfiki T, Stitt L, Yau G, et al. The impact of post-mastectomy radiation therapy on male breast cancer patients—a case series. Int J Radiat Oncol Biol Phys. 2012;82(2):696–700.PubMedCrossRefGoogle Scholar
  95. 95.
    Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.CrossRefGoogle Scholar
  96. 96.
    Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–62.CrossRefGoogle Scholar
  97. 97.
    Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol. 1984;2(8):903–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer. 1984;53(6):1344–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Donegan WL. Cancer of the male breast. In: Donegan WL, Spratt JS, editors. Cancer of the breast. Philadelphia: WB Saunders; 1995. p. 774–5.Google Scholar
  100. 100.
    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002;25(3):235–7.PubMedCrossRefGoogle Scholar
  101. 101.
    Mauras N, O’Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85(7):2370–7.PubMedGoogle Scholar
  102. 102.
    Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol. 2005;90(1):26–30.PubMedCrossRefGoogle Scholar
  103. 103.
    Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT, et al. Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne. 2004;25(4):323–4.PubMedCrossRefGoogle Scholar
  104. 104.
    Labrie F, Dupont A, Belanger A, Lacourcière Y, Béland L, Cusan L, et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med. 1990;13(5):275–8.PubMedGoogle Scholar
  105. 105.
    Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer. 1993;72(2):502–5.PubMedCrossRefGoogle Scholar
  106. 106.
    Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer. 1988;62(3):474–8.PubMedCrossRefGoogle Scholar
  107. 107.
    Chen X, Liu X, Zhang L, Li S, Shi Y, Tong Z. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. Jpn J Clin Oncol. 2013;43(10):954–63.PubMedCrossRefGoogle Scholar
  108. 108.
    Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol. 2010;73(3):246–54.PubMedCrossRefGoogle Scholar
  109. 109.
    Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996;77(3):490–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Donegan WL. Cancer of the male breast. J Gend Specif Med. 2000;3(4):55–8.PubMedGoogle Scholar
  111. 111.
    Foerster R, Foerster FG, Wulff V, Schubotz B, Baaske D, Wolfgarten M, et al. Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer. 2011;11:335.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Tural D, Selcukbiricik F, Aydogan F, Beşe N, Yetmen O, Ilvan Ş, et al. Male breast cancers behave differently in elderly patients. Jpn J Clin Oncol. 2013;43(1):22–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Guinee VF, Olsson H, Moller T, Shallenberger RC, van den Blink JW, Peter Z, et al. The prognosis of breast cancer in males: a report of 335 cases. Cancer. 1993;71(1):154–61.PubMedCrossRefGoogle Scholar
  114. 114.
    Soliman AA, Denewer AT, El-Sadda W, Abdel-Aty AH, Refky B. A retrospective analysis of survival and prognostic factors of male breast cancer from a single center. BMC Cancer. 2014;14:227.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    O’Malley CD, Prehn AW, Shema SJ, Glaser SL. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002;94(11):2836–43.PubMedCrossRefGoogle Scholar
  116. 116.
    Selcukbiricik F, Tural D, Aydogan F, Beşe N, Büyükünal E, Serdengeçti S, et al. Male breast cancer: 37-year data study at a single experience center in Turkey. J Breast Cancer. 2013;16(1):60–5.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Xia Q, Shi YX, Liu DG, Jiang WQ. Clinicopathological characteristics of male breast cancer: analysis of 25 cases at a single institution [in Chinese with English abstract]. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1469–73.PubMedGoogle Scholar
  118. 118.
    Andre S, Fonseca I, Pinto AE, Cardoso P, Pereira T, Soares J, et al. Male breast cancer-a reappraisal of clinical and biologic indicators of prognosis. Acta Oncol. 2001;40(4):472–8.PubMedCrossRefGoogle Scholar
  119. 119.
    Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow S, Winer EP, et al. Quality of life and symptoms in male breast cancer survivors. Breast. 2013;22(2):197–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Abdullah Igci
    • 1
    Email author
  • Mustafa Tukenmez
    • 2
  • Enver Özkurt
    • 2
  1. 1.Istanbul Medical FacultyIstanbul UniversityIstanbulTurkey
  2. 2.Department of General SurgeryIstanbul Medical Faculty, Istanbul UniversityIstanbulTurkey

Personalised recommendations